What it's for (Indications)
- Insulin soluble, including biphasic formulations such as Insuman Comb 25, is primarily indicated for the treatment of diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
- Specifically, it is essential for individuals with Type 1 diabetes (insulin-dependent diabetes mellitus), where the body produces little or no insulin, requiring exogenous insulin for survival.
- For patients with Type 2 diabetes mellitus, insulin therapy is initiated when oral hypoglycemic agents, lifestyle modifications (diet and exercise), or other non-insulin injectable therapies are insufficient to achieve target glycemic control.
- Insuman Comb 25, being a biphasic human insulin, provides both a rapid-onset glucose-lowering effect from its soluble component and a sustained action from its isophane component, making it suitable for patients requiring both post-prandial and basal glycemic control within a single injection regimen.
- It is often utilized in treatment regimens where a fixed ratio of short-acting and intermediate-acting insulin is beneficial, such as in patients adhering to consistent meal schedules.
- Additionally, insulin therapy may be indicated for gestational diabetes if diet and exercise prove inadequate, and in specific acute situations like hyperosmolar hyperglycemic state or diabetic ketoacidosis, although the specific formulation (e.
- g.
- , intravenous regular insulin) may differ for acute emergencies.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of insulin soluble, including biphasic insulins like Insuman Comb 25, must be highly individualized based on the patient's metabolic needs, blood glucose monitoring results, lifestyle (dietary intake and physical activity), and overall clinical status. Insuman Comb 25 is administered via subcutaneous injection, typically into the abdominal wall, thigh, or upper arm, and injection sites should be rotated to prevent lipodystrophy. The frequency of administration for Insuman Comb 25 usually ranges from once to twice daily, taken shortly before meals, often the main meal or the evening meal, as advised by the prescribing clinician. The exact timing relative to meals is crucial for optimal post-prandial glucose control. Dosing adjustments are frequently necessary and should be made under the guidance of a healthcare professional, based on regular self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM) values. Factors such as renal or hepatic impairment, intercurrent illness, concomitant medications, and changes in physical activity or diet may necessitate dose modifications. It is critical for patients to understand the correct preparation and administration technique for their specific insulin pen or syringe, and to never share insulin pens or needles with other individuals, even if the needle is changed, due to the risk of pathogen transmission. |
Safety & Warnings
Common Side Effects
- The most common and clinically significant side effect associated with insulin soluble therapy, including Insuman Comb 25, is hypoglycemia.
- This occurs when blood glucose levels fall too low and can manifest with symptoms such as sweating, tremor, dizziness, confusion, hunger, palpitations, and in severe cases, seizures, unconsciousness, or even death.
- Patients must be educated on recognizing and treating hypoglycemia.
- Other common side effects include injection site reactions, such as pain, redness, swelling, itching, or bruising at the site of injection.
- Prolonged use of insulin at the same site can lead to lipodystrophy, characterized by lipohypertrophy (thickening of fatty tissue) or lipoatrophy (thinning of fatty tissue), which can impair insulin absorption.
- Weight gain is also a frequently observed side effect of insulin therapy, resulting from improved metabolic control and an anabolic effect.
- Less common but potential side effects include allergic reactions, ranging from localized skin rashes to systemic reactions such as generalized urticaria, angioedema, or rarely, life-threatening anaphylaxis.
- Fluid retention and peripheral edema can also occur, particularly during the initiation or intensification of insulin therapy.
- Hypokalemia (low potassium levels) may occur due to the intracellular shift of potassium, particularly in patients with pre-existing risk factors or those receiving high doses of insulin.
Serious Warnings
- Black Box Warning: WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE. Acute bronchospasm has been observed in AFREZZA (inhaled insulin)-treated patients with asthma and Chronic Obstructive Pulmonary Disease (COPD). AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD. Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease.
- Several critical warnings are associated with the use of insulin soluble, including Insuman Comb 25.
- The most prominent warning is the risk of severe hypoglycemia, which can be life-threatening.
- Patients should be educated on the symptoms, causes (e.
- g.
- , missed meals, excessive exercise, incorrect dosage), and emergency management of hypoglycemia.
- Close monitoring of blood glucose is essential.
- Severe hypersensitivity or allergic reactions, including anaphylaxis, can occur and require immediate medical attention.
- It is crucial to rotate injection sites within the same region (e.
- g.
- , abdomen, thigh, arm) to minimize the risk of lipodystrophy, which can affect insulin absorption and glycemic control.
- Insulin pens and needles are for single-patient use only; sharing carries a risk of blood-borne pathogen transmission.
- Dose adjustments may be necessary in patients with renal or hepatic impairment, during periods of illness or stress, or when changing physical activity or dietary habits.
- Concomitant use of thiazolidinediones (TZDs) with insulin can increase the risk of fluid retention and heart failure, necessitating close monitoring for signs and symptoms of heart failure.
- Drug interactions can significantly impact glucose control; medications such as oral contraceptives, corticosteroids, sympathomimetics, beta-blockers, alcohol, and certain antidepressants may either increase or decrease insulin requirements.
- Patients should always inform their healthcare provider of all medications they are taking.
- Unintended medication errors, particularly confusing different insulin types or concentrations, pose a significant risk, and patients must be vigilant about verifying their insulin product before each injection.
How it Works (Mechanism of Action)
Insulin is a potent polypeptide hormone synthesized by the beta cells of the islets of Langerhans in the pancreas. Its primary physiological role is the regulation of glucose homeostasis. Exogenously administered insulin, such as human insulin in soluble forms and biphasic preparations like Insuman Comb 25, exerts its metabolic effects by binding to specific insulin receptors located on the surface of target cells, including hepatocytes, adipocytes, and skeletal muscle cells. This binding initiates a cascade of intracellular signaling events that lead to the translocation of glucose transporters (primarily GLUT4) to the cell membrane in muscle and adipose tissue, thereby facilitating the uptake of glucose from the bloodstream into these cells. Concurrently, insulin inhibits hepatic glucose production by suppressing glycogenolysis (breakdown of glycogen to glucose) and gluconeogenesis (synthesis of glucose from non-carbohydrate precursors). It also promotes the synthesis and storage of glycogen in the liver and muscle. Beyond glucose metabolism, insulin also plays a critical role in lipid metabolism, inhibiting lipolysis (breakdown of fats) and promoting fatty acid synthesis, and in protein metabolism, by enhancing amino acid uptake and protein synthesis while inhibiting protein degradation. Insuman Comb 25 is a biphasic insulin comprising 25% soluble human insulin (rapid-acting component) and 75% isophane human insulin (intermediate-acting component). The soluble component provides an immediate onset of action and a peak effect designed to cover post-prandial glucose excursions, while the isophane component is formulated with protamine and zinc to delay absorption, providing a more prolonged, sustained glucose-lowering effect that addresses basal insulin requirements.
Commercial Brands (Alternatives)
No other brands found for this formula.